In this issue

Hem-Onc
Volume 1, Issue 1
July/August/September 2010
View current issue

Issue Highlights

Call for Papers

Please consider submitting your paper to Hem-Onc. Click here to download our Call for Papers.

Sign up for Table of Contents Alerts

Editor-in-Chief

Jianxiang Wang, M.D.
Chinese Academy of Medical Science and Peking Union Medical College
Tianjin, China

Email the Managing Editor.
Print ISSN: 2150-5632
Online ISSN: 2150-5640

Submit your paper to Hem-Onc

Hem-Onc utilizes an online submission and tracking system designed to provide efficient service to authors. Through the online system, author files are automatically converted to PDFs, submissions are acknowledged by email, and authors can track their manuscript through the stages of the peer review process.

Please click here to submit your paper to Hem-Onc.

Note to Potential Authors

Page and color charges are waived for the first four issues and the final version of accepted manuscripts will be posted on the web site promptly. Any content posted on the web site from now until July 2011 will always be free for registered users. Authors will receive a free print version of the issue containing their paper. For additional information on how to submit your manuscript please visit our Guidelines for Authors.

Original research papers and review articles rejected from high-impact journals, including Nature, Science and Cell may be submitted with previous reviews and decision letters.

About Hem-Onc

Aims and Scope

Hem-Onc aims to serve as an international journal to publish comprehensive and cutting-edge information on basic and (or) applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. A rapid turnaround time from submission to publication means that knowledge and new successes can be shared in real time. The journal will be essential reading for scientists and researchers who wish to keep abreast of the latest developments in the field. The editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies.

Topics of interest include oncogenes, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias, the myelodysplastic syndromes, and marrow or stem cell reconstitution in patients with a wide range of neoplasms.

We will publish the following types of papers:

• Editorials
• "State of the Art" Commentaries and Invited Reviews
• Concise Reviews
• Original Articles
• Brief reportCorrespondence
• Case reports
• Clinical Guidelines
• Meeting Reports
• New Technologies

 

Advertisements